Alseres Pharmaceuticals Inc (CE) (ALSE) Noticias

ALSE: effective December 31,2014 a one for 5,000 reverse split:

http://otce.finra.org/DailyList

Sold mine here today for tax loss.

I dont have anymore shares sold cpl of months back

Artist, Funny, Silver etc.
I also post on CASI, IN CASE THEY MAKE THIS BOARD DISAPPEAR LIKE THEY DID ON YAHOO.
Accurate

Silver,
Please read my recent posts IF YOU ARE A HUGE HOLDER ?
Accurate

The question is are you a huge stockholder, 6 figures in # of shares ? Otherwise after the reverse split it's not gonna help.
If so I've been down this road before and the legal fees can be high but if we band together maybe we can get fair value which will be substantial when they get FDA approval.
If we all, substantial holders, band together we can prevail $ wise.
Accurate

what can you do buddy?

Funny,
See my post to artist today.
CONTACT ME PLEASE.
ACCURATE12200

Artist,
If you or any other holder of ALSE is a large holder please contact me ASAP. ON IHUB IS OK OR ANYWAY.
There is a reverse split happening and we need to coordinate all LARGE holders. Been here before with another issue and we NEED to work together.
SO ALL POSTERS PLEASE REPLY IF YOU HAVE A LARGE NUMBER OF SHARES.
As of Monday you will own 1/5000 of what # you now have, so if you don't have hundreds of thousands of shares you will have very little.
Accurate122000

ALSE 0.03 X 0.0349. CHART SHOWS MM HAS LOADED THE BOTTOM

waiting for some news

ALSE vol. chart seems someone preload 700k back in June. Phase III clinic trial.

Alseres Pharmaceuticals, Inc. (ALSE) is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system (CNS). Our lead product candidate is Altropane®, a proprietary molecular imaging agent used to diagnose Parkinson's disease and dementia. Altropane is presently in Phase III clinical development for the diagnosis of Parkinson's disease. Our development strategy for Altropane anticipates entering into one or more partnerships to ensure development and commercialization of the product.

http://www.alseres.com/

ALSE 10Q: 30.6M OS; Medication Altropane is in phase III clinic trial

As of July 31, 2014, there were 30,635,720 shares of the registrant’s Common Stock issued and outstanding.

ALSE approaching end of phase III clinic trial. bidding some more 0.035, lotto ticket.

Alseres Pharmaceuticals, Inc. (ALSE) is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system (CNS). Our lead product candidate is Altropane®, a proprietary molecular imaging agent used to diagnose Parkinson's disease and dementia. Altropane is presently in Phase III clinical development for the diagnosis of Parkinson's disease. Our development strategy for Altropane anticipates entering into one or more partnerships to ensure development and commercialization of the product.

http://www.alseres.com/

2012 NEWS// HOPKINTON, Mass., July 31, 2012 /PRNewswire/ — Alseres Pharmaceuticals, Inc. (OTC: ALSE) today announced that it has entered into an agreement with Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB, “Navidea”) to license, [(123)I]-E-IACFT Injection (CFT), also called Altropane®, an Iodine-123 radiolabeled imaging agent, being developed as an aid in the diagnosis of Parkinson’s disease and movement disorders.

“We are pleased to have completed this agreement with Navidea. With its focus, dedication, and imaging expertise, Navidea represents an ideal partner to complete the development and commercialization of this promising agent that may help millions of patients with movement disorders arrive at a more timely and accurate diagnosis,” said Peter G. Savas, CEO of Alseres.

“The diagnostic dilemma in movement disorders remains a pressing medical need that will continue to escalate as our world’s population ages,” said Dr. Mark Pykett, President and CEO of Navidea. “The addition of the CFT program is consistent with our growth strategy to build our precision radiopharmaceutical pipeline with later stage, high value diagnostics aimed at important medical needs.”

“We believe that CFT has the potential to be a best-in-class imaging agent to improve diagnostic accuracy by differentiating Parkinson’s disease from non-degenerative movement disorders, especially during the period soon after onset of symptoms,” said Dr. Thomas Tulip, Navidea’ s EVP and Chief Business Officer.

In January 2012, Alseres and Navidea executed an Option Agreement pursuant to which Navidea paid Alseres the non-refundable sum of $500,000 in exchange for the exclusive option to license the CFT program, to conduct its final due diligence review of the program and to prepare the paperwork necessary for the execution of the license.

Under the terms of the license agreement, Alseres granted Navidea an exclusive, worldwide sublicense to research, develop, and commercialize CFT. In connection with the execution of this agreement, Navidea will make a one-time sublicense execution payment to Alseres equal to (i) One Hundred Seventy-Five Thousand Dollars ($175,000) and (ii) issue Alseres 300,000 shares of NAVB common stock.

The license agreement also provides for contingent milestone payments of up to $2.9 million, $2.5 million of which will principally occur at the time of product registration or upon commercial sales, and the issuance of up to an additional 1.15 million shares of Navidea stock, 950,000 shares of which are issuable at the time of product registration or upon commercial sales. In addition, the license terms anticipate royalties on yearly net sales of the approved product which are consistent with industry-standard terms and certain license extension fees, payable in cash and shares of common stock, in the event certain milestones are not met.

Read more at http://www.redorbit.com/news/health/1112667041/alseres_pharmaceuticals_inc_reports_license_of_altropane_worldwide_rights_to/#kQGoiWI6Lj7RMZ2p.99

http://www.biocentury.com/companies/alseres_pharmaceuticals_inc

sure is

ALSE 0.05 WOW! AIR THIN!!

ALSE 0.035 LAST PIG. Company Believes Trial May Have Already Enrolled Enough Subjects to Achieve Statistical Significance

thnx G

ALSE 0.035 interesting. Webpage shows 2014 and their product in phase III clinical developement

Alseres Pharmaceuticals, Inc. (ALSE) is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system (CNS). Our lead product candidate is Altropane®, a proprietary molecular imaging agent used to diagnose Parkinson's disease and dementia. Altropane is presently in Phase III clinical development for the diagnosis of Parkinson's disease. Our development strategy for Altropane anticipates entering into one or more partnerships to ensure development and commercialization of the product.

http://www.alseres.com/

Anyone out there watching this ALSE?

Why did they just spike 125%?

What's going on here?

!!!